Pneumothorax Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Pneumothorax Treatment Market is Segmented By Medication (Local Anesthetics, Opiate Analgesics, Benzodiazepines, Antibiotics, Others), By Treatment Type (Pleurectomy, Bullectomy, Pleurodesis, Others), By Indication (Primary spontaneous pneumothorax Infection, Secondary spontaneous pneumothorax Infection, Injury-related pneumothorax Infection, Tension pneumothorax Infection, Others), By End-User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Pneumothorax Treatment Market is estimated to reach at a high CAGR 4.5% during the forecast period (2023-2030).

A pneumothorax (PTX) is a condition that occurs when air leaks into the space between the lungs and chest wall. It can be caused by a blunt or piercing chest injury, certain medical treatments, or lung illness. Shortness of breath is one of the symptoms. A needle or chest tube is frequently inserted between the ribs to remove the excess air from a pneumothorax. On the other hand, a tiny pneumothorax may heal on its own.

Pneumothorax Treatment Market Dynamics

Advancement in the diagnosis of pneumothorax is expected to drive market growth.

Chest radiography is one of the most cost-effective and widely available diagnostic methods for detecting various chest diseases, including pneumothorax. The researchers are inspired to contribute to the automation of the diagnostic process using chest radiographs by the success of deep learning techniques in other domains of medicine. As a result, various frameworks for automatic pneumothorax detection have been presented, leveraging various machine learning and, in particular, deep learning techniques. Therefore, the current best-performing model for the NIH Chest Xray14 dataset was provided by Baltruschat. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Lack of awareness regarding pneumothorax infections in emerging countries delayed diagnosis and a low incidence of diagnosis, and fewer side effects caused by the drugs are some of the factors the market is expected to hamper the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 viral pneumonia can cause a spontaneous pneumothorax, a rare consequence. The unique respiratory dynamic and the high rate and duration of tracheal intubation have favored the inevitability of upper airway injuries, including mechanically induced tracheal and laryngotracheal tree lesions, as well as lung injury from barotrauma with the onset of pneumothorax and pneumomediastinum. Moreover, due to the limitations typical of an emergency, the diagnosis and proper care of iatrogenic injuries have also suffered. Injury from barotrauma with small and medium-sized airways (pneumomediastinum, pneumopericardium) and pulmonary parenchyma are among the most common clinical images associated with iatrogenic injury (pneumothorax, pneumatoceles).

Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market.

Pneumothorax Treatment Market Segment Analysis

Opiate Analgesics segment is expected to hold the largest market share in pneumothorax treatment market

The opiate analgesics segment is expected to dominate in 2020. The segment benefits because pain control with opiate analgesics is vital for appropriate patient care since it ensures patient comfort and facilitates the pulmonary toilet. Most analgesics contain sedative qualities, which might help patients with painful skin lesions. These medications are necessary for the initial installation of thoracostomy tubes and pain management following the procedure. For instance, Fentanyl citrate (Sublimaze), The onset of analgesia with fentanyl citrate is immediate when administered intravenously (IV), and the analgesia lasts 30-60 minutes. The respiratory depressive effect, on the other hand, may continue longer than analgesia. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Pneumothorax Treatment Market Scope

Pneumothorax Treatment Market Geographical Analysis

North America region holds the largest market share in the global pneumothorax treatment market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of the pneumothorax infection, advancement in diagnosis procedures and FDA Clearance to the market players, is some factors the market is expected to boost in the forecast period. For instance, according to the National Center for Biotechnology Information, Primary spontaneous pneumothorax is most common in people between 20 and 30. PSP affects 7 per 100,000 men and 1 per 100,000 women in the United States each year. Recurrence occurs in most cases within the first year, with rates ranging from 25% to 50%. The first 30 days have the highest recurrence rate.

Moreover, Patients in their 60s and 65s are more likely to develop secondary spontaneous pneumothorax. For men and women, the incidence of SSP is 6.3 and 2 incidences per 100,000 patients, respectively. The ratio of males to females is 3:1. The number of pneumothoraxes per 100,000 people with COPD is 26. Heavy smokers had a 102-fold higher risk of spontaneous pneumothorax than non-smokers. Additionally, On September 13, 2019, The US Food and Drug Administration (FDA) granted 510(k) clearance to GE Healthcare’s artificial intelligence (AI) algorithms, Critical Care Suite, to identify pneumothorax, a type of collapsed lung. Therefore, it has increased the demand for the treatment of pneumothorax, due to which the North American region is expected to hold the largest market share in the forecast period.

Pneumothorax Treatment Market Competitive Landscape

Major key players in the pneumothorax treatment market are Pfizer Inc., Fresenius Kabi USA, Akorn, Inc., Piramal Critical Care, Baxter Healthcare Corporation, Valeant Pharmaceuticals North America LLC, Teva Pharmaceuticals USA, Inc., Comed Chemicals Ltd., UCB, Inc. and Midas Pharma GmbH.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its medicines and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.

­Product Portfolio:

LIDOCAINE HYDROCHLORIDE (lidocaine hydrochloride): Lidocaine HCl stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.

Frequently Asked Questions

What is the Projected CAGR value of the Pneumothorax Treatment Market?

Pneumothorax Treatment Market is expected to grow at a CAGR of 4.5% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Pneumothorax Treatment Market during 2022-2029

Which is the fastest growing region in the Pneumothorax Treatment Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period